检索结果-南通市图书馆

Severe COVID-19 patients exhibit an ILC2 NKG2D^(+) population in their impaired ILC compartment

Cellular & Molecular Immunology 2021年第2期18卷 484-486页

作者： Alejandra Gomez-Cadena Laurie Spehner Marie Kroemer Myriam Ben Khelil Kevin Bouiller Grégory Verdeil Sara Trabanelli christophe borg Romain Loyon Camilla Jandus Department of Pathology and Immunology University of GenevaGenevaSwitzerlandand Ludwig Institute for Cancer ResearchLausanneSwitzerland University of Bourgogne Franche-Comté INSERMEFS BFCUMR1098RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et GéniqueF-25000BesançonFrance Department of Pharmacy University Hospital of BesançonF-25000BesançonFrance Department of Infectious Disease University Hospital of BesançonF-25000BesançonFrance UMR-CNRS 6249 Chrono-Environment UniversitéBourgogne Franche-ComtéF-25000BesançonFrance Department of Oncology UNIL-CHUVUniversity of Lausanne1066EpalingesSwitzerland Department of Medical Oncology University Hospital of BesançonF-25000BesançonFrance

Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)is responsible for the current COVID-19 disease pandemic.In some patients,the symptoms are mild,and a fraction of SARS-CoV-2-infected individuals develop severe illness with a high fatality rate due to lung damage and acute respiratory distress syndrome.1 Innate lymphoid cells(ILCs)are a recently identified type of effector immune cells that rapidly sense environmental stimuli and participate in early immune responses by promptly secreting large amounts of cytokines.2 The ILC2 subpopulation was shown to mediate Type 2 responses and to recruit eosinophils during viral lung infections upon the release of alarmins(e.g.,IL-33)by damaged epithelial cells.3,4,5 ILC2s were also shown to participate in the termination of inflammatory responses and tissue repair by amphiregulin secretion.In addition,ILC2s are critical in the early phases of allergic lung inflammation,including that induced by the protease allergen papain.6 Based on the essential function of the papain-like protease PLpro in regulating SARS-CoV-27(Fig.1a)and the severe lung damage caused by this virus,we sought to investigate the potential involvement of ILC2s in immune responses to COVID-19.

关键词： impaired patients acute

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

CD8^(+)CD226^(high)T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery

引用

Cellular & Molecular Immunology 2023年第4期20卷 365-378页

作者： Julien Viot Syrine Abdeljaoued Angélique Vienot Evan Seffar Laurie Spehner Adeline Bouard Kamal Asgarov Jean-RenéPallandre Elodie Renaude Elodie Klajer ChloéMolimard Franck Monnien Frederic Bibeau Celia Turco Bruno Heyd Paul Peixoto Eric Hervouet Romain Loyon Alexandre Doussot christophe borg Marie Kroemer Department of Medical Oncology Biotechnology and Immuno-Oncology PlatformUniversity Hospital of BesançonBesançonFrance INSERM EFS BFCUMR1098RIGHTUniversity of Franche-ComtéInteractions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et GéniqueBesançonFrance Department of Pathology University Hospital of BesançonBesançonFrance Department of Surgery University Hospital of BesançonBesançonFrance EPIGENEXP platform University of Bourgogne Franche-ComtéBesançonFrance Department of Pharmacy University Hospital of BesançonBesançonFrance

CD226 has been reported to participate in the rescue of CD8^(+)T cell dysfunction.In this study,we aimed to assess the prognostic value of CD226 in tumor-inﬁltrating lymphocytes(TILs)derived from colorectal cancer(CRC)liver metastases treated with chemotherapy and radical surgery.TILs from 43 metastases were isolated and analyzed ex vivo usingﬂow cytometry.CD155 and CD3 levels in the tumor microenvironment were assessed by immunohistochemistry.Exploration and validation of biological processes highlighted in this study were performed by bioinformatics analysis of bulk RNA-seq results for 28 CRC liver metastases pretreated with chemotherapy as well as public gene expression datasets.CD226 expression contributes to the deﬁnition of the immune context in CRC liver metastases and primary tumors.CD226 on CD8^(+)T cells was not speciﬁcally coexpressed with other immune checkpoints,such as PD1,TIGIT,and TIM3,in liver metastases.Multivariate Cox regression analysis revealed CD226 expression on CD8^(+)T cells to be an independent prognostic factor(p=0.003),along with CD3 density at invasion margins(p=0.003)and TIGIT expression on CD4^(+)T cells(p=0.019).CD155 was not associated with the prognostic value of CD226.Gene expression analysis in a validation dataset conﬁrmed the prognostic value of CD226 in CRC liver metastases but not in primary tumors.Downregulation of CD226 on CD8^(+)TILs in the liver microenvironment was restored by IL15 treatment.Overall,CD226 expression on liver metastasis-inﬁltrating CD8^(+)T cells selectively contributes to immune surveillance of CRC liver metastases and has prognostic value for patients undergoing radical surgery.

关键词： CD226 antigen Colorectal Neoplasms Liver metastasis Lymphocytes Tumor-Inﬁltrating

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study

引用

World Journal of Gastrointestinal Oncology 2020年第3期12卷 332-346页

作者： Angélique Vienot Hortense Chevalier Clément Bolognini Elisabeta Gherga Elodie Klajer Aurélia Meurisse Marine Jary Stefano Kim Christelle d’Engremont Thierry Nguyen Fabien Calcagno Hamadi Almotlak Francine Fein Meher Nasri Syrine Abdeljaoued Anthony Turpin christophe borg Dewi Vernerey Department of Medical Oncology Besançon University HospitalBesançon F-25030France University Bourgogne Franche-Comté INSERMEFS BFCUMR1098Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et GéniqueBesançon F-25000France INSERM CIC-1431 Clinical Investigation Center in BiotherapyBesançon University HospitalBesançon F-25030France Department of Medical Oncology Lille University HospitalLille F-59000France Department of Medical Oncology Nord Franche-ComtéHospitalMontbéliard F-25020France Methodological and Quality of Life in Oncology Unit Besançon University HospitalBesançon F-25030France Department of Gastroenterology Besançon University HospitalBesançon F-25030France

BACKGROUND FOLFIRINOX regimen is the first-line reference chemotherapy(L1)in advanced pancreatic ductal adenocarcinoma(aPDAC).FOLFOXIRI,a schedule with a lower dose of irinotecan and no bolus 5-fluorouracil,has demonstrated efficacy and feasibility in colorectal cancer.AIM To investigate the potential clinical value of FOLFOXIRI in patients with aPDAC in routine clinical practice.METHODS Analyses were derived from all consecutive aPDAC patients treated in L1 between January 2011 and December 2017 in two French institutions,with either FOLFOXIRI(n=165)or FOLFIRINOX(n=124)regimens.FOLFOXIRI consisted of irinotecan(165 mg/m2),oxaliplatin(85 mg/m2),leucovorin(200 mg/m2)and 5-fluorouracil(3200 mg/m2 as a 48-h continuous infusion)every 2 wk.Ninety-six pairs of patients were selected through propensity score matching,and clinical outcomes of the two treatment regimens were compared.RESULTS Median overall survival was 11.1 mo in the FOLFOXIRI and 11.6 mo in the FOLFIRINOX cohorts,respectively.After propensity score matching,survival rates remained similar between the two regimens in terms of overall survival(hazard ratio=1.22;P=0.219)and progression-free survival(hazard ratio=1.27;P=0.120).The objective response rate was 37.1%in the FOLFOXIRI group vs 47.8%in the FOLFIRINOX group(P=0.187).Grade 3/4 toxicities occurred in 28.7%of patients in the FOLFOXIRI cohort vs 19.5%in the FOLFIRINOX cohort(P=0.079).FOLFOXIRI was associated with a higher incidence of grade 3/4 digestive adverse events.Hematopoietic growth factors were used after each chemotherapy cycle and the low hematological toxicity rates were below 5%with both regimens.CONCLUSION FOLFOXIRI is feasible in L1 in patients with aPDAC but does not confer any therapeutic benefit as compared with FOLFIRINOX.The low hematological toxicity rates strengthened the relevance of primary prophylaxis with hematopoietic growth factors.

关键词： Advanced pancreatic cancer First-line chemotherapy FOLFOXIRI FOLFIRINOX Propensity score Cohort study

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer

引用

Journal of Cancer Therapy 2013年第1期4卷 165-169页

作者： Erion Dobi Thierry Nguyen christophe borg Xavier Pivot Bernard Royer Stefano Kim Department of Medical Oncology University Hospital of BesanconBesanconFrance Institut National de la Sante et de la Re-cherche Medicale-Unite Mixte de Recherche(INSERM UMR)No.1098 BesanconFrance Department of Pharmacology Univer-sity Hospital of BesanconBesanconFrance

Background: metronomic chemotherapy is based on antiangiogenic and immunologic mechanisms obtained by the administration of traditional cytotoxic drugs at lower concentration without rest periods. The low dosage induces fewer or no side effect compared to classic maximum tolerated dose administration (MTD). At present, no treatment related acute leukaemia was reported in cyclophosphamide-based metronomic chemotherapy (CMC). Case: We report the case of an 81-year-old man considered as having castration and chemo-refractory metastatic prostate cancer. CMC was started. Objective response was observed in this heavily pre-treated patient with progression free survival lasting more than 30 months. No toxicity was observed in this period and his autonomy was maintained. Finally, our patient developed a chemotherapy-induced acute myeloid leukaemia at 36th month of CMC. Conclusion: Even CMC is a well-tolerated treatment;secondary acute leukaemia is related to cumulative dose of cyclophosphamide. The benefit and the risk of long-term exposure to cyclophosphamide should be carefully balanced.

关键词： Metronomic Chemotherapy Cyclophosphamide Prostate Cancer Secondary Acute Leukemia

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

引用

World Journal of Clinical Oncology 2018年第5期9卷 110-118页

作者： CANDice Carola Fran?ois Ghiringhelli Stefano Kim Thierry ANDré Juliette Barlet Le?la Bengrine-Lefevre Hélène Marijon Marie-Line Garcia-Larnicol christophe borg Linda Dainese Nils Steuer Hubert Richa Magdalena Benetkiewicz Annette K Larsen Aimery de Gramont Benoist Chibaudel Department of Medical Oncology Franco-British Institute Department of Medical Oncology Centre George Fran?ois Leclerc Department of Medical Oncology CHU Besan?on Department of Medical Oncology Saint-Antoine Hospital and Sorbonne Universités UMPC Department of Anatomy-Pathology Paris Pathology Institute Department of Gastrointestinal Surgery Franco-British Institute Fondation ARCAD Cancer Biology and Therapeutics Centre de Recherche Saint-Antoine INSERM U938 Faculté de Médecine Sorbonne Université

AIM To evaluate the efficacy and safety of the modified FOLFIRI3-aflibercept as second-line therapy in patients with metastatic colorectal cancer.METHODS This is a retrospective multicenter cohort, evaluating the efficacy and safety of the association of aflibercept with FOLFIRI3(day 1: aflibercept 4 mg/kg, folinic acid 400 mg/m^2, irinotecan 90 mg/m^2, 5-fluorouracil infusion 2400 mg/m^2 per 46 h; day 3: irinotecan 90 mg/m^2) in patients with previously treated metastatic colorectal cancer. The primary endpoint was overall response rate(ORR). Secondary endpoints were disease control rate(DCR), progression-free survival(PFS), overall survival(OS), and safety.RESULTS Among 74 patients treated in four French centers, nine were excluded due to prior use of aflibercept(n = 3), more than one prior treatment line in irinotecanna?ve patients(n = 3), and inadequate liver function(n = 3). In the "irinotecan-na?ve" patients(n = 30), ORR was 43.3% and DCR was 76.7%. Median PFS and OS were 11.3 mo(95%CI: 6.1-29.0) and 17.0 mo(95%CI: 13.0-17.3), respectively. The most common(> 5%) grade 3-4 adverse events were diarrhea(37.9%), neutropenia(14.3%), stomatitis and anemia(10.4%), and hypertension(6.7%). In the "pre-exposed irinotecan" patients(n = 35), 20(57.1%) received ≥ 2 prior lines of treatment. ORR was 34.3% and DCR was 60.0%. Median PFS and OS were 5.7 mo(95%CI: 3.9-10.4) and 14.3 mo(95%CI: 12.8-19.5), respectively.CONCLUSION Minimally modified FOLFIRI has improvement dramatically the FOLFIRI3-aflibercept efficacy, whatever prior use of irinotecan. A prospective randomized trial is warranted to compare FOLFIRI-aflibercept to FOLFIRI3-aflibercept.

关键词： Chemotherapy Irinotecan Aflibercept Second-line Colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：